Form 4: Sage Therapeutics Director Disposes Shares Following Supernus Merger Completion

A director of Sage Therapeutics, George Golumbeski, has reported the disposition of common stock and stock options as a result of the company's merger with Supernus Pharmaceuticals, Inc., effective July 31, 2025.

Summary

• George Golumbeski, a Director of Sage Therapeutics, Inc. (SAGE), reported changes in his beneficial ownership of securities.
• The changes occurred on July 31, 2025, which was the effective time of the merger between Sage Therapeutics, Inc. and Supernus Pharmaceuticals, Inc. (Parent), through its subsidiary Saphire, Inc.
• Pursuant to the merger agreement dated June 13, 2025, a cash tender offer for Sage common stock was completed, followed by a merger.
• At the effective time, each outstanding share of Sage common stock was cancelled and converted into the right to receive $8.50 per share in cash (the 'Closing Amount') plus one contingent value right (CVR) per share.
• Each CVR represents the right to receive up to an additional $3.50 per share in cash upon the satisfaction of specified milestones, as detailed in a Form 8-K filed by Sage on June 16, 2025.
• Mr. Golumbeski disposed of 8,000 shares of common stock, resulting in zero shares beneficially owned directly.
• Stock options with an exercise price less than the $8.50 Closing Amount were fully vested, cancelled, and converted into a cash payment equal to the product of (Closing Amount exercise price) multiplied by the number of shares subject to the option, plus one CVR for each share subject to the option.
• Specifically, 13,593 stock options with an exercise price of $6.14 and 21,500 stock options with an exercise price of $6.77 were disposed of under these terms.
• Stock options with an exercise price greater than or equal to the Closing Amount ($8.50) were cancelled with no consideration.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, providing shareholders and eligible option holders with a defined cash payout and potential future upside via CVRs. While it signifies the end of Sage as an independent entity, the terms appear to be executed as planned, which is generally positive for the involved parties.

Positives

• Shareholders and eligible option holders of Sage Therapeutics received a cash payment of $8.50 per share/option, providing immediate liquidity and value realization.
• The inclusion of a Contingent Value Right (CVR) offers potential for additional cash payments of up to $3.50 per share upon the achievement of specific future milestones, providing upside potential beyond the initial cash consideration.
• Stock options with exercise prices below the merger's closing amount were fully vested and converted into cash and CVRs, benefiting option holders.

Negatives

• Stock options with an exercise price greater than or equal to the $8.50 Closing Amount were cancelled without any consideration, resulting in a loss of value for holders of those options.
• Sage Therapeutics ceases to be an independent publicly traded company, which may limit future growth opportunities for its previous shareholders.

Risks

• The value of the Contingent Value Rights (CVRs) is contingent upon the satisfaction of specified milestones, meaning the full $3.50 per share is not guaranteed and may not be realized.
• The specific milestones for CVR payout were not detailed in this filing, requiring reference to a separate Form 8-K for full understanding of the conditions.

Future Outlook

The merger of Sage Therapeutics into a subsidiary of Supernus Pharmaceuticals is complete, meaning Sage Therapeutics no longer operates as an independent public entity. The future financial performance for former Sage shareholders is now tied to the performance of Supernus Pharmaceuticals and the achievement of the contingent value right milestones.

Industry Context

This merger represents a consolidation event within the biotechnology and pharmaceutical sector, where larger companies often acquire smaller, specialized firms to expand their product pipelines or market reach. Such acquisitions are common strategies for growth and risk diversification in the highly competitive and capital-intensive drug development industry.

Stakeholder Impact

• Shareholders: Received $8.50 cash per share and one CVR per share, converting their equity into cash and a contingent future payment.
• Option Holders: Those with in-the-money options received cash and CVRs, while out-of-the-money options were cancelled without value.
• Employees: Employees holding stock options would have their options treated as described, potentially receiving cash and CVRs.

Next Steps

• Monitoring the achievement of specified milestones for the Contingent Value Rights (CVRs) to determine if the additional $3.50 per share payment will be realized.

Key Dates

Keywords

Sage Therapeutics, Supernus Pharmaceuticals, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Contingent Value Right, SAGE, Corporate Action